• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心Castleman 病致不可逆性肾损害。

Irreversible Kidney Damage due to Multicentric Castleman's Disease.

机构信息

Department of Infectious Disease.

出版信息

Libyan J Med. 2008 Jun 1;3(2):101-3. doi: 10.4176/080108.

DOI:10.4176/080108
PMID:21499466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3074288/
Abstract

Castleman's Disease (CD) is a rare lymphoproliferative disorder accompanied by marked systemic inflammatory response. Morphological diagnosis of CD requires biopsy of the whole of the involved lymph node tissue. Three histologic variants have already been described in CD morphology (hyaline vascular, plasma-cell, and mixed). In this study, we report a case of a multicentric Castleman's disease of the plasma cell variant type with negative Herpes Virus 8. The clinical presentation of this patient was of systemic amyloidosis as a result of both a delayed diagnosis and medical management. Previously described cases of CD with secondary amyloidosis have been of the localized type. Regardless, long-standing clinical remission of CD by cytotoxic drugs and anti-CD20 antibody therapy was achieved, but the nephrotic syndrome remained irreversible.

摘要

卡斯尔曼病(CD)是一种罕见的淋巴组织增生性疾病,伴有明显的全身炎症反应。CD 的形态学诊断需要对整个受累淋巴结组织进行活检。CD 的形态学已经描述了三种组织学变异(透明血管型、浆细胞型和混合型)。在本研究中,我们报告了一例浆细胞变异型多中心卡斯尔曼病,疱疹病毒 8 阴性。该患者的临床表现为系统性淀粉样变性,这是由于诊断和医疗管理的延误。以前描述的伴有继发性淀粉样变性的 CD 病例为局限性类型。然而,通过细胞毒性药物和抗 CD20 抗体治疗实现了 CD 的长期临床缓解,但肾病综合征仍然不可逆转。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3e4/3074288/5af17c7429f1/LJM-3-101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3e4/3074288/4b7779fb9789/LJM-3-101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3e4/3074288/5af17c7429f1/LJM-3-101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3e4/3074288/4b7779fb9789/LJM-3-101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3e4/3074288/5af17c7429f1/LJM-3-101-g002.jpg

相似文献

1
Irreversible Kidney Damage due to Multicentric Castleman's Disease.多中心Castleman 病致不可逆性肾损害。
Libyan J Med. 2008 Jun 1;3(2):101-3. doi: 10.4176/080108.
2
A multicentric, hyaline vascular variant of Castleman's disease associated with B cell lymphoma: a case report.多中心性透明血管型Castleman病合并B细胞淋巴瘤:一例报告
Cases J. 2009 Jun 10;2:8183. doi: 10.4076/1757-1626-2-8183.
3
[Clinical analysis on giant lymph node hyperplasia on neck].[颈部巨大淋巴结增生症的临床分析]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Mar;44(3):223-6.
4
Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.与多中心Castleman病相关的肾血栓性微血管病。两例报告。
Am J Surg Pathol. 1995 Sep;19(9):1021-8. doi: 10.1097/00000478-199509000-00005.
5
Unicentric Castleman's disease associated with end stage renal disease caused by amyloidosis.与淀粉样变性所致终末期肾病相关的单中心Castleman病。
World J Clin Cases. 2017 Mar 16;5(3):119-123. doi: 10.12998/wjcc.v5.i3.119.
6
Castleman's disease of the spleen.脾脏的卡斯尔曼病
World J Gastroenterol. 2015 Feb 7;21(5):1675-9. doi: 10.3748/wjg.v21.i5.1675.
7
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.单中心和多中心Castleman病的管理:16例报告及文献复习
Cancer. 1999 Feb 1;85(3):706-17. doi: 10.1002/(sici)1097-0142(19990201)85:3<706::aid-cncr21>3.0.co;2-7.
8
Multicentric Castleman's disease in a child with prominent thymic involvement: a case report and brief review of the literature.一名胸腺受累显著的儿童多中心Castleman病:病例报告及文献简要回顾
Mod Pathol. 1993 Nov;6(6):776-80.
9
Presentation and Outcome of Castleman's Disease in Immunocompetent Hosts.免疫功能正常宿主中Castleman病的临床表现及转归
Indian J Hematol Blood Transfus. 2016 Dec;32(4):468-474. doi: 10.1007/s12288-015-0602-6. Epub 2015 Oct 1.
10
Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report.肾移植术后Castleman病在移植肾切除术后缓解:一例报告
Transplant Proc. 2007 May;39(4):1276-7. doi: 10.1016/j.transproceed.2007.03.059.

本文引用的文献

1
Treatment of Castleman's disease.卡斯尔曼病的治疗。
Curr Treat Options Oncol. 2005 May;6(3):255-66. doi: 10.1007/s11864-005-0008-z.
2
The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.50 年来Castleman病的病因及管理:将病理生理学转化为患者护理
Br J Haematol. 2005 Apr;129(1):3-17. doi: 10.1111/j.1365-2141.2004.05311.x.
3
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.利妥昔单抗在一种与免疫现象相关的侵袭性多中心Castleman病中的疗效。
Am J Hematol. 2005 Apr;78(4):302-5. doi: 10.1002/ajh.20283.
4
Fifty years of multicentric Castleman's disease.五十年的多中心性Castleman病。
Acta Oncol. 2004;43(8):698-704. doi: 10.1080/02841860410002752.
5
Human herpesvirus 8 (HHV-8/KSHV) and hematologic malignancies.人类疱疹病毒8型(HHV-8/卡波西肉瘤相关疱疹病毒)与血液系统恶性肿瘤
Rev Clin Exp Hematol. 2003 Dec;7(4):375-405.
6
Localized mediastinal lymphnode hyperplasia resembling thymoma.类似胸腺瘤的局限性纵隔淋巴结增生
Cancer. 1956 Jul-Aug;9(4):822-30. doi: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4.
7
A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.一例多中心Castleman病合并晚期系统性淀粉样变性,接受化疗和抗CD20单克隆抗体治疗。
Ann Hematol. 2003 Dec;82(12):766-8. doi: 10.1007/s00277-003-0718-x. Epub 2003 Jul 30.
8
Secondary amyloidosis in Castleman's disease: review of the literature and report of a case.Castleman病中的继发性淀粉样变性:文献综述及一例报告
Ann Hematol. 2002 Jun;81(6):336-9. doi: 10.1007/s00277-002-0444-9. Epub 2002 May 17.
9
Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease.单中心Castleman病合并系统性AA型淀粉样变性:一种可治愈的疾病。
QJM. 2002 Apr;95(4):211-8. doi: 10.1093/qjmed/95.4.211.
10
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.与血清淀粉样蛋白A蛋白循环浓度相关的AA型淀粉样变性中的淀粉样蛋白负荷及临床结局
Lancet. 2001 Jul 7;358(9275):24-9. doi: 10.1016/S0140-6736(00)05252-1.